Vertex Pharmaceuticals forecast annual revenue largely above Wall Street estimates on Monday, banking on robust sales of its ...
Two sizable companies and a handful of small Asian issuers were listed in the US this past week. Read more here.
Sionna Therapeutics SION) stock rises as the clinical-stage biopharma focused on cystic fibrosis therapies makes its public ...
The FDA has granted priority review to brensocatib to treat patients with non-cystic fibrosis bronchiectasis, according to a ...
Despite new medication, cystic fibrosis often leads to permanent lung damage. Working with an international team, researchers ...
The biotech is evaluating several cystic fibrosis medicines that could either work alongside Vertex’s top-selling Trikafta or ...
Vertex Pharmaceuticals Inc. will soon lose a member of its leadership team that helped the company achieve major revenue growth over the past decade.
The FDA has started a priority review of Insmed's brensocatib, which is pitching to become the first approved therapy for ...
The Massachusetts-based biotech plans to use the funds to push its candidates into mid-stage clinical trials in a space ...
A study led by TUM researchers finds that cystic fibrosis alters immune cells early in life, likely before birth. These ...
Despite new medication, cystic fibrosis often leads to permanent lung damage. Working with an international team, researchers from the Technical University of Munich (TUM) have discovered that the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback